Loading data for PRNAF — first visit, this takes a few seconds.
Alterity Therapeutics Limited (PRNAF): cotización, análisis y datos
Valor intrínseco
Pronóstico del analista
Previsiones bursátiles →Últimos resultados
| Reportado | Vs. estimación | Cambio interanual | |
|---|---|---|---|
| Ingresos | — | n/a | n/a |
| EPS | — | n/a | n/a |
Métricas
- Precio de compra
- 0.36
- Ingresos (TTM)
- 3.61M
- Beneficio neto (TTM)
- -23.4M
- -0.04
- -0.08
- n/a
- n/a
- P/B (TTM)
- 2.84
- P/S (TTM)
- 24.21
- Fecha de resultados
- n/a
- Precio de venta
- 0.44
- Volumen
- 2,500
- Volumen medio (20D)
- 161
- Abierto
- 0.40
- Anterior Cerrar
- 0.40
- Rango del día
- 0.40 - 0.40
- Rango de 52 semanas
- 0.00 - 0.55
- analista
- n/a
- Precio objetivo
- n/a
- Dividendos
- n/a
- Fecha ex dividendo
- n/a
Acerca de Alterity Therapeutics Limited
Ver perfil →Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as bioMUSE, biomarkers of progression in multiple system atrophy. The company also operates drug discovery platform that generates patentable chemical compounds to treat the underlying pathology of neurological diseases. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Industria Biotechnology
Sector Healthcare
IPO Fecha Sep 25, 2012
Empleados 11
Bolsa de Valores OTC Markets OTCPK
Símbolo bursátil PRNAF
Sitio web https://alteritytherapeutics.com